Good-pond/decent-fish with an asterisk: DefenCath holds a genuine FDA regulatory monopoly in hemodialysis CRBSI prevention, but operates inside an oligopsonistic customer base (two LDOs control ~70% of outpatient dialysis), and FY2025 profitability was built entirely on TDAPA premium pricing that expires July 1 2026. Post-acquisition of Melinta, CRMD is now a diversified acute-care specialty pharma platform — which reduces single-product risk but adds integration complexity from a previously bankrupt asset.

| | | |---|---| | Ticker | CRMD (NASDAQ) | | Price | $8.81 | | Market Cap | $680M | | Shares Out | 78.4M (as of 2026-03-31) | | Sector | Pharmaceuticals | | Rating | 5.5 / 10 — Mixed | | Risk Badge | YELLOW | | Classification | TDAPA-cliff transition — profitable specialty pharma at a reimbursement reset |

---

CorMedix Inc is a commercial-stage specialty pharmaceutical company. Its flagship product, DefenCath (taurolidine/heparin catheter lock solution), is the only FDA-approved antimicrobial catheter lock solution in the United States, approved to reduce catheter-related bloodstream infections (CRBSIs) in adult hemodialysis patients who use central venous catheters. In August 2025, CorMedix acquired Melinta Therapeutics for $300M ($260M cash + $40M equity + up to $25M in milestones), adding six hospital anti-infectives: MINOCIN (minocycline IV), REZZAYO (rezafungin), VABOMERE (meropenem/vaborbactam), ORBACTIV (oritavancin), BAXDELA (delafloxacin), and KIMYRSA (oritavancin IM), plus TOPROL-XL (metoprolol succinate, cardiology).

---

• Navigating the post-TDAPA reimbursement transition for DefenCath (July 1 2026 onward)
• Pursuing REZZAYO sNDA for fungal prophylaxis in allogeneic HSCT patients (H2 2026 submission planned)
• Advancing Phase 3 TPN trial for DefenCath (completion now guided 2028)
• Executing $75M share buyback program
• Pursuing Medicare Advantage contracting for DefenCath (no timeline guided)
• Integrating Melinta portfolio and driving Melinta revenue growth

---

Revenue (from SEC XBRL fact sheet):

| FY | Revenue | |---|---| | 2022 | $0.07M | | 2023 | not reported in XBRL | | 2024 | $43.5M | | 2025 | $311.7M |

Note: FY2025 revenue jump ($43.5M → $311.7M) reflects DefenCath's full TDAPA year plus eight months of Melinta contribution post-close (August 2025).

Operating Income (from SEC XBRL fact sheet):

| FY | Operating Income | |---|---| | 2023 | -$49.0M | | 2024 | -$22.4M | | 2025 | +$150.1M |

The company recorded operating losses in every year from 2010 through 2024 — 15 consecutive years of operating losses. FY2025 is the first profitable year, coinciding exactly with the TDAPA premium window.

Operating Cash Flow (from SEC XBRL fact sheet):

| FY | OCF | |---|---| | 2023 | -$38.4M | | 2024 | -$50.6M | | 2025 | +$175.0M |

Balance Sheet & Runway:

• Cash at FY2025 year-end: $144.8M (SEC XBRL confirmed)
• Cash at Q1 2026 end: $178.1M (per company reporting; not in XBRL fact sheet)
• 2026 adjusted EBITDA guidance: $115-135M
• No going-concern language in recent filings
• Adequate runway through the H2 2026 pricing reset without equity issuance

Share Count / Dilution (from SEC XBRL fact sheet):

| Period End | Shares | |---|---| | 2023-12-31 | 54.9M | | 2024-12-31 | 64.4M | | 2025-12-31 | 79.3M | | 2026-03-31 | 78.4M (modest buyback reduction) |

+44% share count growth in two years. The Melinta deal included a $40M equity component. The $75M buyback program ($11.1M executed in Q1 2026) is a partial offset but the dilution tail is already baked in.

---

Current multiples (fact sheet + guided figures):

• Market cap: $680M at $8.81/share (fact sheet)
• FY2025 OCF: $175M → EV/OCF ≈ 2.9-3.1x (using $144.8M year-end 2025 cash for EV adjustment)
• 2026 adjusted EBITDA guidance: $115-135M → EV/EBITDA ≈ 4.0-4.6x
• 8-analyst average price target: ~$15 (MarketBeat, 6 Buy / 2 Hold)

Fair value range: $10–$14 per share

Method: If 2027 plays out as management's base case — DefenCath $100-125M + Melinta ~$120M = ~$220-245M net revenue, sustained $100-120M adjusted EBITDA — and the market assigns 5-6x EV/EBITDA on a cash-generative multi-product specialty pharma with ~$178M cash, equity value lands in roughly $11-14 per share. The low end ($10) reflects a scenario where CMS methodology disappoints and Melinta run-rate stays flat. The $200M+ REZZAYO prophylaxis option is not in this range and represents pure optionality above it.

Note: These figures incorporate external guidance data not fully confirmed in the XBRL fact sheet; treat as directional.

---

• Institutional ownership: 54.7% (MarketBeat)
• Insider ownership: 8.78%
• $75M buyback authorized (Board, early 2026); $11.1M executed in Q1 2026
• No dividend
• New institutional positions from smaller funds (Ultra-Small Company Fund, Lighthouse Investment Partners) reported while stock remains depressed
• Year-over-year stock down ~35% as of mid-May 2026

---

At $8.81 and ~$680M market cap, CRMD trades at roughly 2.9-3.1x FY2025 EV/OCF for a business that:

• Has a genuine FDA regulatory monopoly in hemodialysis CRBSI prevention (no approved competitor)
• Has patent protection through 2033 per company filings
• Generated $175M OCF and $150M operating income in FY2025 — the first profitable year after 15 years of losses
• Holds $144.8M cash at year-end 2025 (per fact sheet), growing further in Q1 2026
• Has 2026 adjusted EBITDA guidance of $115-135M — enough to weather H2 2026 price compression without touching capital markets
• Has a REZZAYO Phase III win (April 27 2026) opening a fungal prophylaxis sNDA with peak sales estimates above $200M annually — entirely outside current guidance and analyst consensus
• Has an entirely unmonetized Medicare Advantage patient population (50%+ of ESRD patients) that could re-rate the DefenCath volume ceiling if contracted

The January 2026 guidance-cut selloff (~30%) pulled the stock to levels where the bear scenario (2027 DefenCath $100-125M + Melinta ~$120M) is essentially already priced in. Any of the three primary catalysts (favorable 2027 CMS methodology, second LDO win, REZZAYO prophylaxis approval) would represent upside the market has not modeled.

---

1. TDAPA cliff is real and confirmed (July 1 2026) DefenCath's TDAPA premium expires June 30 2026. Company guided 'significant reduction in institutional reimbursement and corresponding net pricing in Q3 and Q4 2026.' Q1 2026 DefenCath revenue was $97.5M including a $9.0M non-recurring favorable adjustment — the H2 2026 run-rate will be materially lower. Severity: High.

2. 2027 DefenCath revenue is guided LOWER than 2026 Company's own 2027 DefenCath guidance: $100-125M. 2026 guidance: $150-170M. Management's '3-5x improvement' language describes the add-on versus H2 2026 (a very low base), not versus TDAPA-era levels. 'Recovery' is a relative framing that masks an absolute decline from peak. Severity: High.

3. CMS 2027 add-on methodology not finalized The entire 2027 recovery narrative depends on CMS using the same calculation methodology. If CMS changes its approach, the improvement could be significantly less than management projects. Severity: Medium.

4. Single-LDO concentration Only one large dialysis organization is confirmed as a customer. DaVita and Fresenius together control ~70% of outpatient dialysis. A second LDO is explicitly excluded from guidance. Failure to sign the second major LDO structurally caps DefenCath's outpatient volume at roughly 35% of the market. Severity: High.

5. 44% share dilution in two years Shares outstanding: 54.9M (end-2023) → 79.3M (end-2025) per fact sheet — a 44% increase. The $75M buyback ($11.1M executed Q1 2026, ~$44M/yr annualized pace) does not offset the prior issuance trail within any near-term horizon. Severity: Medium.

6. Melinta was a bankrupt asset CorMedix paid $300M for a portfolio that previously went through bankruptcy. Q1 2026 Melinta contribution was $29.9M, annualizing to ~$120M — consistent with pre-deal estimates but showing no post-acquisition acceleration. Mature declining assets (BAXDELA, ORBACTIV) drag on portfolio growth. The main growth driver (REZZAYO prophylaxis) depends on an sNDA not yet submitted. Severity: Medium.

7. TPN trial slipping 12-18 months The Phase 3 TPN trial previously guided to complete H1 2027 now guided to complete 2028. Enrollment is at ~one-third of patients needed for interim analysis. This pushes the next meaningful DefenCath diversification catalyst back by 12-18 months. Severity: Medium.

8. FY2025 profitability is entirely TDAPA-era The company lost money in every year from at least 2010 through 2024 (per fact sheet: 15 consecutive years of operating losses). The jump from -$22.4M operating income (FY2024) to +$150.1M (FY2025) coincides exactly with the TDAPA window. The underlying post-TDAPA business has never demonstrated standalone profitability. Severity: Medium.

9. Medicare Advantage wall 50%+ of ESRD patients are in MA plans that negotiate pricing far more aggressively than fee-for-service Medicare. More than 90% of current DefenCath utilization is in fee-for-service. No timeline for MA contracting. Severity: Medium (double-edged: bull optionality if solved, structural cap if not).

---

-

Share count anomaly in fact sheet (2017-2018): Shares show 71.4M at end-2017 dropping to 21.8M at end-2018. This likely reflects a reclassification or restatement in XBRL reporting rather than a reverse split, but warrants verification in actual 10-K filings before drawing conclusions.

• Vizient Innovative Technology designation (October 2025): Vizient is the largest US healthcare GPO. This designation eases formulary access for DefenCath in hospital settings — relevant for the future TPN indication even though it is not a direct revenue catalyst today.
• FY2024 OCF was -$50.6M (fact sheet) — worse than FY2023's -$38.4M — because the Melinta acquisition was in process and TDAPA revenues ramped through the year. The $300M Melinta deal closed in August 2025 and was financed primarily from FY2025 TDAPA cash flows ($175M OCF), though the +14.8M share increase in FY2025 suggests meaningful equity co-financing.

-

Achaogen cautionary comp: ZEMDRI (plazomicin) was FDA-approved June 2018 and the company filed for bankruptcy by June 2019. FDA approval of a first-in-class hospital anti-infective is not a commercial guarantee. CRMD's multi-product platform post-Melinta is more defensible than a single-product antibiotic, but the dynamic is relevant.

---

CRMD is a genuine TDAPA-cliff story trading at a real-business multiple. The monopoly is real (only FDA-approved antimicrobial catheter lock solution, no approved competitor), the cash generation was real (FY2025 OCF $175M, fact-sheet confirmed), and the REZZAYO Phase III win (April 27 2026) is real optionality not yet in any guidance. But the bear case is equally real: profitability was built on a time-limited CMS pricing bonus, 2027 revenue is guided lower than 2026 even in management's base case, the second LDO is uncontracted, and Melinta was a bankrupt asset showing no post-acquisition acceleration.

The honest set-up: the stock already priced in the TDAPA cliff (down ~30-35% on January 2026 guidance), so the risk-reward depends almost entirely on whether the 2027 CMS methodology, a second LDO, or REZZAYO prophylaxis fires — none of which is in guidance. The cash balance ($144.8M at year-end 2025; $178.1M at Q1 2026 per company reporting) and 2026 EBITDA guidance ($115-135M) mean survival through the H2 2026 pricing reset is not in question. The question is whether the 2027 and beyond business generates $100M+ in annual EBITDA to justify the current market cap, or reverts toward a $50-75M EBITDA business where the $680M valuation looks stretched.

Fair-value range: $10-14/share in the base case, with optionality above that if REZZAYO prophylaxis or a second LDO materializes.

---

Research, not investment advice. Figures sourced from SEC filings and public data; verify before acting.

Institutional: 54.7% | Insider: 8.78% | Buyback: $75M authorized, $11.1M executed Q1 2026 (per external reporting)